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Summary 
The host response to Borrelia burgdorferi is likely to play a role in the pathogenesis of Lyme arthritis. 
Whereas most patients with Lyme arthritis can be cured with antibiotic therapy, ~10% of the 
patients have persistent arthritis for months or even several years after antibiotic treatment. In 
this study, we tested the hypothesis that the T cell response to one or more antigens of/~ burgdo~ri 
is different in patients with treatment-responsive or treatment-resistant Lyme arthritis. For this 
purpose, 313/~ burgdorferi-specific T cell lines were derived from the synovial fluid or peripheral 
blood of four patients with treatment-responsive Lyme arthritis and five patients with treatment- 
resistant  arthritis. 87 T  cell lines from treatment-responsive Lyme arthritis and 112 lines from 
the treatment-resistant group were examined for the recognition of five recombinant. B. burgdorferi 
proteins: outer surface proteins A (OspA), B, C, p39, and p93. In both groups of patients, the 
T cell lines frequently recognized OspB, and only occasionally recognized OspC, p39, and p93. 
In contrast, OspA was preferentially  recognized by T cell lines from patients with treatment- 
resistant arthritis, but only rarely recognized by T cell lines from patients with treatment-responsive 
arthritis (odds ratio 28.4, 95% confidence interval 9.2-87.8, p <0.005). These results are compatible 
with the hypothesis that the T cell response to/~ burgdorferi OspA is involved in the pathogenesis 
of treatment-resistant Lyme arthritis. 
"[me  borreliosis,  a  tick-borne  infection caused  by  the 
spirochete Borrelia burgdorferi, is a multisystem disorder. 
A characteristic skin lesion, erythema migrans, accompanied 
by meningitis- or flu-like symptoms, is often the first sign 
of the disease (1, 2). The spirochetes frequently disseminate, 
and neurologic or cardiac symptoms or migratory  joint pain 
may develop weeks to months after the infection. Months 
later, ~60% of untreated North American patients develop 
intermittent attacks of monoarticular or oligoarticular arthritis, 
primarily in large joints. Particularly  during the second or 
third year of the illness, '~ 10% of patients with arthritis de- 
velop continuous  joint inflammation for 1 yr or longer, which 
we have termed "chronic Lyme arthritis" (3, 4). Lyme ar- 
thritis coexists with specific and strong humoral and cellular 
immune responses  to B. burgdorferi (5-10). 
Patients with Lyme arthritis usually respond to antibiotic 
therapy (11-13); however, in ",210% of patients with arthritis, 
the inflammation persists despite antibiotic therapy (11, 13, 
14). Careful analysis of the treatment responses in a recent 
cohort of patients with Lyme arthritis led to the concept of 
dividing patients with Lyme arthritis into two groups: those 
with treatment-responsive Lyme arthritis, defined as resolu- 
tion of arthritis within 3 mo after the initiation of appro- 
priate antibiotic treatment; and those with treatment-resistant 
arthritis, which lasts for more than 3 mo after the initiation 
of treatment (13). Spirochetes have occasionally been seen in 
or isolated from the synovium of patients with Lyme arthritis 
(15, 16) and a few spirochete-like  structures have also been 
detected in the synovium of some patients with chronic Lyme 
arthritis after antibiotic treatment (17). Recently, PCR has 
been shown to provide a sensitive and reliable method for 
the detection of/g burgdorferi DNA in synovial fluid (SF)  1 
in patients with Lyme arthritis (18, 19). Whereas Borrelia 
DNA can be amplified reliably from pretreatment samples 
of SF, it has been shown that most patients who have persis- 
tent Lyme arthritis  despite multiple courses  of antibiotic 
therapy yield consistently negative PCR test results in SF 
after antibiotic treatment (18, 19). Thus, although Lyme ar- 
1 Abbreviations used in this paper: EBV-BCL, EBV-transformed B call line; 
MBP, maltose binding protein; OspA, OspB, OspC, outer surface protein 
A, B, C; PB, peripheral blood; SF, synovial fluid; TCL, T cell line. 
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ongoing synovial inflammation in patients with treatment- 
resistant arthritis may be caused by factors other than persis- 
tent/g  burgdorferi infection. 
Host  factors  have  been  linked  to  the  pathogenesis  of 
treatment-resistant Lyme arthritis. The presence of the HLA- 
DR4 specificity in patients with Lyme arthritis  was found 
to be associated with a lack of response to antibiotic therapy 
(20).  Among HLA-DR4 + patients,  those with  IgG anti- 
bodies against outer surface protein A  (OspA) or OspB of 
t~ burgdorferi had arthritis for significantly longer after treat- 
ment than those who lacked reactivity with these proteins 
(10). Most recently, the HLA-DR4 specificity and the level 
of IgG reactivity with OspA were each reported to be a risk 
factor for treatment-resistant Lyme arthritis and the presence 
of both factors doubled the risk of this outcome (13).  The 
synovial lesion in patients with chronic Lyme arthritis  is similar 
to that seen in other forms of chronic inflammatory arthritis, 
including rheumatoid arthritis. Villous hypertrophy, vascular 
proliferation, and a lymphoplasmaceUular infiltrate  are present 
(15,  17).  There  is intense  HLA-DR and  -DQ  expression 
throughout the lesion,  and the T cells are mostly CD4 + (17), 
Lyme arthritis is one of the few forms of chronic inflam- 
matory arthritis in which the cause is known with certainty. 
Therefore,  the study of B  burgdo~'eri-specific  T  cells from 
patients with Lyme arthritis provides an opportunity to in- 
vestigate the role of T cells in the pathogenesis of this form 
of inflammation. If there is a role for T cells in the pathogen- 
esis of treatment-resistant Lyme arthritis, two competing hy- 
potheses  need  to  be  considered.  First,  the  patients  with 
treatment-resistant arthritis might lack the particular T cells 
needed to eradicate/~  burgdorferi from the host because of 
a hole in the T cell repertoire. In such patients, B. burgdorferi 
may persist, thereby maintaining chronic synovial inflamma- 
tion. Alternatively,  the patients with treatment-resistant Lyme 
arthritis  might  have  autoreactive T  cells that  are activated 
during/g  burgdorferi infection of the joint.  These cells may 
then maintain chronic inflammation for a period of months 
after eradication  of the  spirochete. 
We have started to test the hypothesis that in patients with 
treatment-resistant  Lyme arthritis,  a T  helper cell response 
induced by one or more/g burgdorferi  antigens results in chronic 
synovial inflammation.  This hypothesis leads to the testable 
prediction  that  the T  helper cell response to B.  burgdorferi 
in patients with treatment-responsive Lyme arthritis  differs 
from that in patients with treatment-resistant  arthritis.  Pos- 
sible differences between the two patient populations include 
epitopes  recognized  or  cytokines  produced  by R  burgdor- 
fin'-specific T cells. In this report, T cell lines (TCL) derived 
from  the  SF  or  peripheral  blood  (PB)  of patients  with 
treatment-responsive or treatment-resistant arthritis were ex- 
amined for their recognition of/~ burgdorferi lysates and five 
of the major spirochetal antigens: p22 (OspC), p31 (OspA), 
p34 (OspB),  p39,  and p93. 
Materials and Methods 
Pat/ents.  For these studies, nine representative patients, four with 
treatment-responsive  and five with treatment-resistant  Lyme ar- 
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thritis, were chosen from patients seen in the Lyme Disease Clinic 
at New England Medical Center. All nine patients, who came from 
the northeastern  United States, met established clinical and sero- 
logic criteria for the diagnosis of Lyme arthritis  (21). They had 
intermittent  episodes of arthritis or chronic arthritis in one or both 
knees, sometimes preceded by erythema, migrans,  and they had 
markedly elevated IgG antibody responses to/g burgclo~'eri  (see Table 
1). The protocol and consent forms for these studies were approved 
by the Human Investigation Review Committee of New England 
Medical Center.  Blood and joint fluid were drawn on the same 
day. Samples from patients with treatment-responsive arthritis were 
obtained  before antibiotic  therapy. Samples from patients  with 
treatment-resistant  arthritis  were obtained  after antibiotic  treat- 
ment. The treatment-resistant  patients were referred to our clinic 
after treatment by their physicians with antibiotic therapy. During 
this study, it became possible to test for B~ burgdorferi  DNA in SF 
by PCR (18). Before this time, joint fluid was obtained in the pres- 
ence of heparin, a known inhibitor of PCR amplification (22), and 
therefore these samples could not be used for PCR. In the other 
five patients,  an aliquot of SF was obtained without heparin for 
PCR testing. 
lg  burgdo~feri Lysates.  The  N40  strain  of/~  burgdo~ri  was 
propagated  in Barbour-Stoenner-Kdly  (BSK) medium  with 6% 
rabbit  serum (both from Sigma Chemical Co., St. Louis, MO). 
Bacteria were grown for 5-7 d at 33~  harvested by centrifuga- 
tion at 15,000 g for 20 min, and washed three times in PBS, soni- 
cated, and filtered (0.2/~m).  The protein content  was estimated 
by spectrophotometry (OD 280 rim), aliquots were made and stored 
at  - 70~ 
Constructs  for Recombinant R  burgdorferi  Proteins.  p22 (OspC), 
p31 (OspA), p34 (OspB), and p93 were produced as maltose binding 
protein  (MBP) fusion proteins and p39 was used as lysates from 
transformed Escherichia  coli. The construct into which the ospA gene 
from R  burgdo~ri strain B31 had been cloned, as described (10), 
was provided by Dr.  R. Kalish (New England Medical Center). 
The constructs containing  the ospC gene or the gene for the 93- 
kD antigen from R  burgdorferi  strain 297 have been described ear- 
lier (23) and were provided by Dr. B. Fung (New England Medical 
Center).  The plasmid pSPR33  with a restriction  fragment  con- 
taining gene coding for the 39-kD protein of the R burgdo~feri  strain 
Sh-2-82 (24) was a gift  from Dr.  T. Schwan (Rocky Mountain 
Laboratories, Hamilton,  MT). 
To produce the MBP-OspB fusion protein,/g burgdo~ri strain 
G39/40 genomic DNA was isolated as described (25). 1-10 ng 
G39/40 genomic DNA was used as template in subsequent PCR 
amplifications. The oligonucleotides 5'GGGATCCTGTGCACA- 
AAAAGGTGCTGAG3' and 5'CCGTCGACCTTCCTACACTAG- 
CTGATTGC3'  were used as 5' and 3' primers, respectively. The 
primer sequences were deduced from the published nucleotide se- 
quence of the closely related/g  burgdo~ri strain B31 (26) and con- 
tained restriction  enzyme digestion sites to allow for directional 
in-frame insertion. The purified PCR products were digested with 
SalI and BamHI, and ligated into the vector pmalCRI (New En- 
gland Biohbs, Inc., Beverly, MA) which carries the ma/E gene under 
the control of the inducible Pt~ promoter. The construct obtained 
codes for OspB amino acids 16-296,  the whole mature  protein 
without the signal sequence (26). 
Sequencing of Constructs.  To confirm the correct insertion and 
orientation  of the constructs before producing  recombinant pro- 
teins, all plasmid DNAs were partially sequenced by the dideoxy 
chain termination method, using modified T7 polymerase in a com- 
mercially available  kit (Sequenase|  United States Biochemical  Corp., 
Cleveland, OH) according to the manufacturer's  instructions. 
Expression of Recombinant Proteins.  E. coli strain 71.18 was trans- 
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duced, lysed, and the crude cell extracts purified over an amylose 
column as described before (10). mAbs H 5332 (27), H 6831 (28), 
L22 1F8 (29), and D7 (30), were used to verify the presence of 
OspA, OspB, OspC, and p93, respectively.  E. coli strain XLl-blue 
was transformed with pSPR33, and lysates were obtained as de- 
scribed above. Lysates  from untransformed XL1 blue were produced 
to serve as controls in our experiments, mAb p39, which was also 
provided to us by Dr. T. Schwann, was used to detect p39 in the 
lysates. 
TCL.  Mononuclear ceils were obtained from heparinized PB 
or  SF  by  the  Ficoll-Hypaque  method  (lymphocyte  separation 
medium  [LSM]; Organon Teknika, Durham, NC). The mono- 
nuclear cells were plated in 96-well  plates (Costar Corp., Cambridge, 
MA) in a final volume of 200 #I at a density of 106 cdls/ml in 
complete medium containing RPMI 1640 (GIBCO BRL, Gaithers- 
burg,  MD) with 5% human AB serum (Sigma Chemical Co.), 
10 mM glutamine, penicillin (100 U/ml), streptomycin  (100/,g/ml), 
2  x  10 -S M 2-ME, and 10 mM Hepes buffer. Sonicated/g  burg- 
do~ri lysate  was added at a final concentration of 10-20/~g/ml. 4 d 
later, human recombinant IL-2, (final  concentration, 5 U/ml; Cetus, 
Emeryville, CA) and Ib4 (final concentration 5 U/ml; Schering- 
Ploegh, Bloomfield, NJ) were added to the plates. The cells were 
expanded in the same medium for 18-21 d. Subsequent additions 
of medium, IL-2, and IL-4  were necessary during this period. After 
this growth period, the viable T cells  were retrieved through Ficoll- 
Hypaque separation. Aliquots of the TCL were used for assays and 
restimulation with antigen. Irradiated (3.5 Gy) autologous PBMC 
at a T cell/PBMC ratio of 1:2.5 were used as APC for the first 
restimulation.  After the first restimulation,  irradiated (8-10 Gy) 
autologous EBV-transformed B cell lines (EBV-BCL)  were used as 
APC.  The TCL were maintained through several rounds of an- 
tigen stimulation  and rest. After the first or second antigen ex- 
posure, TCL were tested for recognition of/i burgdo~ri in prolifer- 
ation assays. The/~ burgdo~ri-specifir TCL were then tested for 
recognition of the recombinant proteins after the second or third 
antigen exposure. 
EBV-BCL.  107 PBMC  were  resuspended in  complete  FCS 
medium (same as complete medium except that 10% FCS [Sigma 
Chemical Co. or GIBCO BRL] was used instead of human AB 
serum). To this suspension supernatant from the chronically EBV- 
infected  marmoset cell line B95-8 (gift from Dr. D. Thorley-Lawson, 
Tufts University) and cyclosporin A (Sandoz, East Hanover, NJ) 
were added. Transformed  cells  were then expanded  in complete FCS 
medium. 
T Cell Proliferation Assays.  TCL were tested for responsiveness 
to antigen in a standard proliferation assay as described earlier (31). 
Negative controls consisted of  no antigen and the appropriate con- 
trol antigen (e.g., untransformed E. coli lysates for p39 or MBP-B- 
Gal-cx alone for the MBP fusion proteins). Positive controls were 
stimulated with PHA (0.5-1/~g/ml, final concentration).  2.5  x 
104 T cells and the same number of irradiated autologous EBV- 
BCL were plated in triplicate in 96-well plates (Costar Corp.) with 
complete medium  alone or in the presence of antigen in a final 
volume of 100 #l/well. Antigen concentrations for the assays were 
titrated  over a range that had been determined to be optimal in 
earlier experiments:/i burgdo~ri lysate was used at 10-20/xg/ml, 
MPB-~-Gal-ol and the MBP fusion proteins were used at 0.03-3 
/xM, and p39 and untransformed  XL1 blue E. coli were used at 
dilutions of lysates ranging from 1:150 to 1:4050. To measure lym- 
phocyte proliferation,  [3H]TdR (1 #Ci/well) in 50/xl complete 
medium was added to each well after a 72-h incubation. The cells 
were harvested 18 h later with an automated harvester and incor- 
porated thymidine was detected in a liquid scintillation counter 
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(Top Count; Packard Instruments, Meridien, CT). Results, which 
are the mean values of triplicate cultures, are calculated as counts 
per minute with background subtracted (Acpm). A result was con- 
sidered positive if the cpm (test) was at least twice the cpm (con- 
trol) and the Acpm was >1,000. 
Immunofluorescent  Staining and Flow Cytometry.  Cells  were stained 
at  106  cdls/100-/~l  sample for  20  rain  at  4~  in  PBS/I% 
BSA/0.1% NAN3. The fluorescin-coupled  rnAbs recognizing CD3 
(OKT3; Ortho Diagnostic Systems, Raritan, NJ), TCR-cx//3  (TCR- 
or/B-l, Becton Dickinson & Co., San Jose, CA), TCR-'y/fi (TCR- 
3'/&l, Becton Dickinson & Co.), CD4 (OKT4A, Ortho), and CD8 
(CD8;  Caltag Laboratories, South San Francisco) were used ac- 
cording to the manufacturers instructions. Isotype-matched FITC- 
or PE-coupled antibodies were used as negative controls. The cells 
were then analyzed on a FACScan  |  (Becton Dickinson & Co.) flow 
cytometer. 
Results 
Clinical Characteristics  of the Patients with Lyme Arthritis.  The 
ages of the nine patients with Lyme arthritis ranged from 
4 to 67 yr (mean 42 yr); seven were men and two were women. 
Of the nine patients, four responded to treatment with 1-mo 
courses of oral doxycycline or amoxicillin plus probenecid. 
They had the onset of symptoms of Lyme disease  a mean 
duration of 7 mo before testing; arthritis was evident for a 
mean of 2 mo during that period, and they had the resolu- 
tion of arthritis within 1 to 3 mo after the initiation of treat- 
ment. In both patients in this group in whom PCK testing 
for/i burgdorferi DNA was done, the results were positive 
in SF before antibiotic treatment (Table 1). The other five 
patients had persistent arthritis, despite treatment with these 
antibiotic regimens and, in three instances, i.v. treatment with 
ceftriaxone for 3-6 wk. PCK testing for/g burgdo(eri DNA 
was done in three patients in this group after antibiotic treat- 
ment; the results were negative. Similar to the patients with 
treatment-responsive arthritis, they had the onset of symp- 
toms of Lyme disease a mean duration of 8 mo before testing. 
However, during that period they had arthritis for a mean 
duration of 5 mo and they had persistent arthritis for 6->24 
mo (mean,  14 mo) after antibiotic treatment.  The clinical 
characteristics of the nine patients are summarized in Table 1. 
B,  buredorferi-specific T  Cell Lines from PB and SF of Pa- 
tients with Lyme Arthritis.  We derived 375 TCL from the 
PB or SF of the nine patients. The 224 TCL derived from 
SF showed a very high frequency (97%) of specificity for 
17, burgdorferi, whereas 63% of the 152 TCL obtained from 
PB were/i burgdorferi-specific (Table 2). Thus, a total of 313 
tt, burgdorferi-specific TCL were derived from the SF and PB 
of these patients. 
The proliferative responses of  individual TCL obtained from 
SF were similar to the responses of TCL obtained from PB. 
As demonstrated in Fig. 1 for one representative patient (RB), 
the mean Acpm _+ SEM for the SF-derived TCL was 20,822 
_+  3,925 and for the PB-derived TCL was 14,795  _+  5,842. 
Similar results were obtained for the other eight patients. 
Of note,/i burgdorferi-specific TCL were obtained from the 
PB and SF of patients RB, TB, and CD, in whose SF/i burg- 
dorferi DNA was no longer detectable by PCR (RB, TB, and 
CD;  see Tables  1 and 2). Table  1.  Clinical  Characteristics of the Nine Patients with Lyme Arthritis 
Duration 
Lyme arthritis 
Lyme  Before  After  IgG response  to 
Patient  Age  Sex  disease*  treatment  treatment  B.  burgdorferi*  PCR  s 
mo 
FD  50  M  1  1  3  1:25,600  + 
AL  67  M  14  5  3  1:25,600  + 
TP  49  M  12  1  3  1:  6,400  ND 
MS  55  F  1  1  1  1:  3,200  ND 
RB  52  M  10  8  8  1:  800  - 
TB  4  M  0.25  0.25  6  1:  3,200  - 
CD  36  F  23  11  15  1:  3,200  - 
JP  35  M  1  1  >24  1:25,600  ND 
DS  30  M  6  6  15  1:  3,200  ND 
* All manifestations of Lyme disease, including Lyme arthritis. 
* ELISA. 
Detection of B. burgdorfer/DNA  in the patient's SF by PCR. Patients FD and AL were tested before antibiotic therapy. No later sample was avail- 
able since treatment was effective. Patients RB, TB, and CD with  therapy-resistant arthritis were tested after antibiotic treatment; pretreatment 
SF samples were not available from these patients. 
FACS  |  analysis of 23 randomly selected fl burgdor.feri-spedfic 
TCL  derived  from  the  SF  or  PB  of two  patients  with 
treatment-responsive Lyme arthritis and three patients with 
treatment-resistant Lyme arthritis showed that all lines were 
CD3 + ,  CD4 +,  TCR-odfl +, CD8-,  and TCR-'y/~-  (data 
not  shown). 
Table  2.  TCL from the Nine Patients with Lyme Arthritis 
B.  burgdorferi-specific/total 
Patient  From PBMC  From SFMC 
Therapy-  FD  6/9  9/9 
responsive  AL  12/14  13/13 
arthritis  TP  7/7  5/5 
MS  4/5  96/96 
Therapy-  RB  16/21  29/30 
resistant  TB  4/4  7/7 
arthritis  CD  11/13  20/20 
JP  20/40  27/32 
DS  15/38  12/12 
Total  95/151  218/224 
The number of B burgdotferi-spedfic  TCL and the number of TCL tested 
from each patient's PB and SF are shown. 
T  Cell Recognition of Recombinant  li burgdorferi Proteins in 
Patients with  Treatment-responsive Arthritis.  We analyzed 62 
lg burgdorferi-specific TCL derived from the SF and 25 TCL 
derived from PB of four patients with treatment-responsive 
Lyme arthritis. Since these lines are polyclonal, they have the 
potential to recognize more than one/~ burgdorferi antigen. 
Overall, OspB was the most frequently recognized antigen 
by both SF-TCL and PB-TCL. However, each patient had a 
different pattern of antigen recognition. For example,  67% 
of the 36 SF-TCL tested from patient MS recognized p39, 
and she was the only patient whose TCL recognized this an- 
tigen.  All  11 SF- and PB-TCL from patient TP recognized 
OspC, and recognition of this antigen was unusual in other 
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patients.  In patient AL, although two of the eight PB-TCL 
recognized OspB, none of the 13 SF-TCL recognized any of 
the five/~ burgdo[feri antigens tested. Fig. 2, A  and B illus- 
trates the range of observed reactivities for the 36/~ burgdor- 
flri-specific SF-TCL derived from patient MS. These lines pref- 
erentially recognized OspB and p39, as shown by the mean 
_+  SEM of the responses depicted in Fig. 2 A  and by the 
individual responses of the 36 TCL demonstrated in Fig. 2 
B. In summary, OspB  was frequently recognized in three 
of the four patients, p39 and OspC were recognized primarily 
by one patient each, and p93 and OspA were rarely recog- 
nized by all four patients  (Table 3). 
T Cell Recognition of Recombinant 1~ burgdorferi Proteins in 
Patients with Treatment-resistant  Lyme Arthritis.  We analyzed 
74 TCL derived from the SF and 38 PB-TCL in the five pa- 
tients with treatment-resistant  arthritis.  In striking contrast 
with the findings in treatment-responsive patients, OspA was 
the preferentially recognized antigen in those with treatment- 
resistant arthritis (Table 4). Of the 112 SF- and PB-TCL, 67 
recognized OspA.  OspB  was  also frequently recognized 
(59/112 SF- and PB-TCL).  Patient JP was the exception: of 
the 22 SF- and PB-TCL from this patient, only two recog- 
nized OspA and two recognized OspB. TCL from this group 
of patients recognized OspC (15/112), p39 (10/112), and p93 
(7/112) at a lower frequency than OspA and OspB. Fig. 3 
shows that OspA and OspB were the most frequently recog- 
nized antigens for the 23/~ burgdorferi-specific SF-TCL from 
a typical patient,  RB.  Thus,  in patients  with treatment- 
resistant arthritis OspA and OspB were frequently recognized 
by T cells from both SF and PB, whereas OspC, p93, and 
p39 were seldomly recognized. 
When  the  responses  were compared in  patients  with 
treatment-responsive  or treatment-resistant  arthritis,  OspB 
was a major antigen in both groups,  whereas OspC, p39, 
and p93 were usually recognized with relatively  low frequency. 
The major difference between the groups was the T cell rec- 
ognition of OspA.  Among the five recombinant proteins 
tested, OspA was the antigen most frequently recognized by 
TCL from patients  with treatment-resistant  Lyme arthritis 
(68/112),  whereas this antigen was least frequently recog- 
nized by TCL from patients  with treatment-responsive  ar- 
thritis  (5/87).  Comparing  SF-TCL  from  patients  with 
treatment-resistant or treatment-responsive arthritis, the odds 
ratio for OspA recognition is 28.4 (95% confidence interval, 
9.2-87.8). This difference  is statistically significant (,v <0.005). 
Discussion 
Lyme arthritis is a suitable model to study chronic synovial 
inflammation for three reasons: The inciting agent,/~ burg- 
dorferi, is known (32), histopathologicaUy Lyme arthritis  is 
similar to other forms of chronic synovial inflammation, in- 
cluding rheumatoid arthritis (15, 17), and Lyme arthritis can 
be differentiated into two forms-one responding and the 
other resistant  to antibiotic therapy  (13). It has long been 
speculated that the host response to B. burgdorferi contributes 
to the pathogenesis of chronic Lyme arthritis (1, 2, 33). There- 
fore, it is of interest to compare the recognition of/g burgdor- 
fer/antigens by TCL derived from patients with the two forms 
of Lyme arthritis. 
To date, one group has published reports on antigen rec- 
ognition by/g burgdorferi-specific cloned TCL derived from 
patients with Lyme disease. They described T ceU dones recog- 
nizing OspA (34, 35), OspB (35), flagellin (8), heat shock 
protein (HSP60) (8), and HSP70 (35). We analyzed the T 
cell response to five/g burgdorferi proteins,  three of which 
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Lyme Arthritis 
Patient  Bb.  OspA  OspB  OspC  p39  p93 
n  n  %  n  %  n  %  n  %  n  % 
FD  9  2  22  8  89  2  22  0  0  1  11 
SF-TCL  AL  13  0  0  0  0  0  0  0  0  0  0 
TP  4  1  25  2  50  4  100  0  0  0  0 
MS  36  1  3  15  42  3  8  24  67  5  14 
Total  62  4  7  25  40  9  15  24  39  6  10 
FD  6  0  0  6  100  0  0  0  0  0  0 
PB-TCL  AL  8  1  13  2  25  1  13  0  0  0  0 
TP  7  0  0  0  0  7  100  0  0  0  0 
MS  4  0  0  2  50  1  25  0  0  0  0 
Total  25  1  4  10  40  9  36  0  0  0  0 
The numbers (percentage) of B. burgdorferi (Bb)-specific SF-TCL and PB-TCL specific for each recombinant antigen are shown. 
(OspC, p39, and p93) have not been studied before.  The fact 
that R  burgdorferi-specific  TCL  could be derived from SF 
samples  in which/~ burgdolferi was no longer detectable by 
PCR, deserves comment. Although PCR detection of/$ burg- 
dorferi has been shown to be extremely sensitive (19, 36, 37), 
it remains possible  that the number of spirochetes  in PCR- 
negative SF samples was too small for detection or that/g burg- 
dorferi organisms were still present in the synovial tissue  or 
other sites although absent from the SE  In the absence  of 
viable spirochetes,/~  burgdo~feri proteins might still be present 
in the synovium, similar to what has been found in Yersinia- 
induced reactive arthritis  (38). Finally, T cell memory is likely 
to be long-lived, even in the absence  of antigen  (39).  The 
pertinent point from our study is that a strong/~  burgdor- 
fer/-specific  T  cell  response  could  be  detected  whereas 
spirochetes  were either present in very small numbers or ab- 
sent  altogether. 
Three features emerge from our study comparing TCL from 
Table  4.  Recognition of Five Recombinant Proteins by B.  burgdorferi-specific TCL from Five Patients with  Therapy-resistant 
L yme Arthritis 
Patient  Bb  OspA  OspB  OspC  p39  p93 
SF-TCL 
Total 
PB-TCL 
Total 
n  n  %  n  %  n  %  n  %  n  % 
RB  23  21  91  18  78  7  30  0  0  2  9 
TB  7  7  100  7  100  0  0  0  0  0  0 
CD  17  8  47  7  41  4  33  2  16  0  0 
JP  15  1  7  1  7  0  0  1  7  0  43 
DS  12  12  100  11  92  2  17  2  17  3  43 
74  49  66  44  60  13  18  5  7  5  7 
RB  8  4  50  3  38  0  0  1  13  2  25 
TB  3  3  100  2  67  0  0  0  0  0  0 
CD  15  5  33  4  27  2  13  1  7  3  20 
JP  7  1  14  1  14  0  0  0  0  0  0 
DS  5  5  100  5  100  0  0  0  0  0  0 
38  18  47  15  40  2  5  2  5  5  13 
The numbers (percentage) of B. burgdorferi (Bb)-specific SF-TCL and PB-TCL specific for each recombinant antigen are shown. 
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Figure 3.  [3H]Thymidine incorporation of 23 fl burgdo~feri-spedfic SF- 
TCL from patient RB (treatment-resistant  Lyme arthritis). (A) Mean cpm 
-+ SEM for all 23 SF-TCL. Background is not subtracted but shown in 
the three leftmost columns for medium alone (open bar), MBP alone (hatched 
bar), and E. coli XLI-blue alone (crosshatched bar). (B) Individual represen- 
tation of the SF-TCL recognizing the five recombinant/t burgdorferi pro- 
teins tested. Data points are shown with background subtracted (Acpm). 
the two groups of patients. First,  OspB was recognized at 
high frequency by T cells from patients with either form of 
Lyme arthritis. Second, OspC, p39, and p93 were recognized 
by TCL from both groups of patients but in most instances 
these antigens were recognized at low frequency. Finally, the 
most important finding of our study was the differential rec- 
ognition of OspA: it was the most frequently recognized an- 
tigen by TCL from patients with treatment-resistant  arthritis, 
whereas it was the least frequently recognized antigen by TCL 
from those with treatment-responsive arthritis (p <0.005). 
How should the differential recognition of OspA by TCL 
from patients with treatment-resistant or treatment-responsive 
Lyme arthritis be interpreted? Since the IgG response to OspA 
2075  Lengl-JanBen et al. 
appears late,  if at all, in patients with Lyme disease (5),  a 
T cell response against OspA in treatment-resistant patients 
might simply be due to the duration of infection: the longer 
the disease duration, the more likely the development of an 
anti-OspA response. However, the period from the onset of 
Lyme disease to the onset of Lyme arthritis was similar in 
the two groups of patients: 7 mo for the treatment respon- 
sive and 8 mo for the treatment-resistant group (Table 1). 
Furthermore, OspA was frequently recognized by TCL from 
patient TB (Tables 1 and 4). These TCL were derived only 
3 mo after the onset of the disease. In addition, our findings 
fit with previous work, which showed a significant associa- 
tion between IgG antibody reactivity to OspA and treatment- 
resistant arthritis (10). Such an association was not found with 
late neurological manifestations of Lyme disease (10). 
If the sole cause for treatment-resistant Lyme arthritis was 
persistent infection with/g burgdorferi, one could hypothe- 
size that all patients initially have OspA-specific T cells, but 
this reactivity disappears  in  the patients with  treatment- 
responsive arthritis after eradication of the spirochete. In con- 
trast, in the patients with treatment-resistant  arthritis,/~ burg- 
dorf~ and OspA-specific T cells may persist.  However, the 
fact that the samples in the patients with treatment-responsive 
arthritis were obtained before treatment argues against this 
interpretation. 
Our data strongly indicate that a T cell response to OspA 
does not protect from Lyme arthritis. On the contrary, our 
finding that OspA is differentially recognized by TCL from 
the two groups of patients is compatible with the hypothesis 
that the T cell response to OspA is involved in the pathogen- 
esis of the chronic synovial inflammation in these patients. 
Two models, which are not mutually exclusive, could help 
explain an OspA-induced pathogenic immune response. Cross- 
reactivity ("molecular mimicry") (40), of a self-antigen with 
a T cell epitope on OspA could overcome T  cell tolerance 
to a self-antigen present in the joint. A search of the Gen- 
Bank, EMBL, and Swissprot databases did not reveal significant 
sequence homologies of OspA with human proteins. How- 
ever, not all potential stir-antigens are included in these data- 
bases. Furthermore, in experimental autoimmune encephalo- 
myelitis in mice, it has recently been shown that peptides 
containing only four or five native residues of the encephalito- 
genic 11 amino acid peptide could induce the disease (41). 
Therefore, it is conceivable that an epitope with only limited 
homology to a self-antigen might induce cross-reactivity. 
According to the second model, non-B~ burgdorferi-specific 
potentially autoreactive "bystander" cells could be activated 
within the joint./~ burgdorferi is known to be a strong in- 
ducer of IL-1 (42) and TNF-ol (43) production  by mononuclear 
cells. We and others have shown that certain substances such 
as bacterial toxins (31, 44), IL-1 (45),  or IL-2 (46, 47) can 
interfere with T cell tolerance. According to this model, the 
acute synovial inflammation caused by infection with/g burg- 
dorferi allows the influx of self-reactive T cells into the syno- 
vium where they could overcome self-tolerance. 
However, our data do not provide experimental proof for 
a detrimental effect of a patient's T cell response against OspA. 
In fact, only 1/15 SF-TCL from one patient with treatment- resistant arthritis recognized OspA. Thus, other factors, per- 
sistent/~ burgdorferi infection or host factors, must also be 
important in the pathogenesis of chronic synovial inflamma- 
tion. The cytokine profile of/~ burgdorferi-specific  T cells is 
likely to be such a factor. Earlier studies on cloned PB-TCL 
from patients with Lyme disease (8) and cloned SF-TCL from 
patients with reactive arthritis (48, 49) found a predominance 
of T cells producing I1-2 and IFN-3', but not IL-4 and IL-5 
(Thl cells). This has led to the idea that a Thl-like pattern 
of cytokine production may be important in the pathogen- 
esis of Lyme and reactive arthritis. Analysis of the cytokines 
produced by the TCL described here will allow us to com- 
pare cytokine patterns in patients with treatment-responsive 
and treatment-resistant  arthritis. 
In our study, OspB was recognized with high frequency 
by TCL from patients with either treatment-responsive  or 
treatment-resistant Lyme arthritis. This is in agreement with 
earlier work in which 8 of 43 R  burgdorferi-specific  T  cell 
clones derived from the PB of a patient with acute Lyme ar- 
thritis recognized OspB (35). The amino acid sequences of 
OspA and OspB of the prototypical North American/~ burg- 
dorferi strain B31 are 56% identical with long stretches of 
sequence identity (up to 13 amino acids). T cell clones recog- 
nizing homologous peptide epitopes on OspA and OspB have 
been described (35). Thus, it is surprising to find no cross- 
reactivity with OspA among the many OspB-specific TCL 
that we derived from patients with treatment-resistant  Lyme 
arthritis. Mapping of the OspB epitopes recognized by TCL 
from patients with treatment-responsive  Lyme arthritis should 
provide an answer to this  question. 
In experimental models of Lyme disease, injection of mAbs 
against OspA (50) as well as active immunization with OspA, 
have been shown to protect mice from infection with/~ burg- 
dorferi (51-55).  The protection seems to be mediated both 
by killing of the spirochete within the host at the time of 
inoculation  and by elimination  of the spirochete from the 
vector ticks feeding on immunized mice (56). These findings 
have led to the development of an OspA-based vaccine for 
human use which is currently undergoing clinical trials (33). 
In healthy individuals, in whom the spirochete is not present, 
we would not predict any immunopathological side effects 
of the vaccination of humans with OspA.  However, there 
is the potential for concern if a vaccinated person is exposed 
later to R  burgdorferi.  If the patient's  antibodies do not kill 
the spirochete in the feeding tick, exposure to B. burgdorferi 
might induce immunopathological T  cell responses. 
Precedence  for such a possibility comes from the experience 
with a vaccine against respiratory  syncytial virus that was 
used in the 1960s. Although the vaccine induced strong sero- 
logical responses, the vaccinees were not protected against 
disease. Moreover, they were at markedly increased risk of 
developing severe  lower respiratory tract disease  when infected 
with the virus, as compared with unimmunized  controls (57). 
In addition, animal models have shown that protective T cell 
responses can also cause immunopathology  (58). For example, 
adoptive transfer of pathogen-specific TCL potentiated clin- 
ical disease  in recipient mice upon infection with the pathogen. 
However, the same TCL did not cause pathology in unin- 
fected mice (59, 60). Similar evidence comes from experi- 
ments with transgenic mice expressing lymphocytic  chorio- 
meningitis virus proteins in pancreatic  islet cells. T cells specific 
for the transgenic proteins were unresponsive in these mice. 
Upon infection with lymphocytic choriomeningitis,  how- 
ever, T  cells infiltrated and destroyed the pancreatic islets, 
and the animals developed diabetes (61, 62). Thus, the pres- 
ence of potentially  immunopathogenic T cells alone is not 
sufficient to induce tissue damage. Only if the host is subse- 
quently infected with the microorganism carrying the specific 
epitope are all the necessary signals delivered for T cell acti- 
vation  (for a review see reference 63). According to these 
findings, the possibility exists that immunopathological effects 
of an OspA-based vaccine might not be seen unless the vac- 
cinees were later exposed to R  burgdorferi. 
In summary, our data show that OspA is differentially rec- 
ognized by TCL from patients with treatment-responsive or 
treatment-resistant  Lyme arthritis. Although we cannot rule 
out that treatment-resistant  Lyme arthritis  is due to persis- 
tent infection with/~ burgdorferi,  and more work is needed 
to further characterize the differential response to OspA, our 
findings are compatible with a role for OspA-specific T cells 
in the immunopathogenesis of therapy-resistant  Lyme arthritis. 
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